Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aquestive Therapeutics, Inc. (AQST : NSDQ)
 
 • Company Description   
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.

Number of Employees: 142

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.03 Daily Weekly Monthly
20 Day Moving Average: 1,245,836 shares
Shares Outstanding: 99.33 (millions)
Market Capitalization: $400.29 (millions)
Beta: 1.97
52 Week High: $5.80
52 Week Low: $2.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 21.75% 17.19%
12 Week 60.56% 35.05%
Year To Date 13.20% 6.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
30 TECHNOLOGY DRIVE
-
WARREN,NJ 07059
USA		 ph: 908-941-1900
fax: -		 investorrelations@aquestive.com http://www.aquestive.com
 
 • General Corporate Information   
Officers
Daniel Barber - President and Chief Executive Officer
Gregory B. Brown - Chairman
A. Ernest Toth, Jr. - Senior Vice President; Chief Financial Officer
Abigail L. Jenkins - Director
John S. Cochran - Director

Peer Information
Aquestive Therapeutics, Inc. (GSAC)
Aquestive Therapeutics, Inc. (CASI)
Aquestive Therapeutics, Inc. (ALCD.)
Aquestive Therapeutics, Inc. (OMNN)
Aquestive Therapeutics, Inc. (CGPI.)
Aquestive Therapeutics, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 03843E104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 99.33
Most Recent Split Date: (:1)
Beta: 1.97
Market Capitalization: $400.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 7.38
EPS Growth
vs. Year Ago Period: -41.18%
vs. Previous Quarter: -26.32%
Sales Growth
vs. Year Ago Period: -27.65%
vs. Previous Quarter: -26.52%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -50.31
12/31/24 - -38.51
Current Ratio
06/30/25 - -
03/31/25 - 4.87
12/31/24 - 4.68
Quick Ratio
06/30/25 - -
03/31/25 - 4.48
12/31/24 - 4.36
Operating Margin
06/30/25 - -
03/31/25 - -100.02
12/31/24 - -76.68
Net Margin
06/30/25 - -
03/31/25 - -100.02
12/31/24 - -76.68
Pre-Tax Margin
06/30/25 - -
03/31/25 - -100.05
12/31/24 - -76.70
Book Value
06/30/25 - -
03/31/25 - -0.61
12/31/24 - -0.66
Inventory Turnover
06/30/25 - -
03/31/25 - 2.52
12/31/24 - 2.57
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©